Serveur d'exploration Tocilizumab - Checkpoint (PubMed)

Index « MedMesh.i » - entrée « Sweden »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Sus scrofa < Sweden < Sweet Syndrome  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 13.
Ident.Authors (with country if any)Title
000328 (2019) C. Turesson [Suède] ; O. Börjesson [Suède] ; K. Larsson [Suède] ; A J Mohammad [Suède] ; A. Knight [Suède]Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis.
000350 (2019) Kathrine Lederballe Gr N [Oman] ; Elizabeth V. Arkema [Suède] ; Bente Glintborg [Danemark] ; Frank Mehnert [Danemark] ; Mikkel Stergaard [Danemark] ; Lene Dreyer [Danemark] ; Mette N Rgaard [Danemark] ; Niels Steen Krogh [Danemark] ; Johan Askling [Suède] ; Merete Lund Hetland [Danemark]Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
000382 (2019) Diederik De Cock [Belgique] ; Patrick Verschueren [Belgique]Primus inter pares: the choice of biologic drugs in rheumatoid arthritis.
000536 (2019) Thomas Frisell [Suède] ; Johan Askling [Suède]Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply.
000537 (2019) Thomas Frisell [Suède] ; Johan Askling [Suède]Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply.
000538 (2019) Hasan Sat ; Gülce Ecem Can [Turquie] ; Reyhan Bilici Salman ; Asl Han Avano Lu Güler ; Hazan Karadeniz ; Abdurrahman TufanComment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register.
000539 (2019) Andrew N B. Weil [Royaume-Uni]Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from a nationwide Swedish register.
000745 (2018) Thomas Frisell [Suède] ; Eva Baecklund [Suède] ; Karin Bengtsson [Suède] ; Daniela Di Giuseppe [Suède] ; Helena Forsblad-D'Elia [Suède] ; Johan Askling [Suède]Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
000803 (2018) Anne HolbrookIn patients with rheumatoid arthritis, bDMARD therapy was not associated with malignant neoplasms.
000B13 (2017) Hjalmar Wadström [Suède] ; Thomas Frisell [Suède] ; Johan Askling [Suède]Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
000B76 (2017) Tanja Schj Dt J Rgensen [Danemark] ; Carl Turesson [Suède] ; Meliha Kapetanovic [Suède] ; Martin Englund [Suède] ; Aleksandra Turkiewicz [Suède] ; Robin Christensen [Danemark] ; Henning Bliddal [Danemark] ; Pierre Geborek [Suède] ; Lars Erik Kristensen [Danemark]EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
000E55 (2016) Anders Gülfe [Suède] ; Johan K. Wallman [Suède] ; Lars Erik Kristensen [Danemark]EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
001142 (2015) Helena Forsblad-D'Elia [Suède] ; Karin Bengtsson [Suède] ; Lars Erik Kristensen [Suède] ; Lennart T H. Jacobsson [Suède]Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/MedMesh.i -k "Sweden" 
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/MedMesh.i  \
                -Sk "Sweden" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Sweden
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021